AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35406491
Drug: Post-chemotherapy CA27.29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-chemotherapy CA27.29 assessment
Trial: 35407553
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg daily for 23 patients, 30 mg daily for 2 patients)
Trial: 35410197
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate 150 mg once monthly for 1 year
Trial: 35410326
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of alcohol/drugs prior to intercourse (sometimes)
Trial: 35410326
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of alcohol/drugs prior to intercourse (always)
Trial: 35410326
Drug: Any HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any HIV treatment literacy
Trial: 35410449
Drug: CoMDA-ML (Quadratic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoMDA-ML (Quadratic Discriminant Analysis algorithm)
Trial: 35410912
Drug: Body iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body iron stores (BIS) measured by serum ferritin and serum transferrin receptor
Trial: 35410912
Drug: Daily smoking,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smoking, hypertension, and increased resting heart rate
Trial: 35412069
Drug: Mirabegron treatment
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron treatment for UUI
Trial: 35412216
Drug: batoclimab 680
RxNorm normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: batoclimab 680 mg
Trial: 35412216
Drug: batoclimab 340
RxNorm normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: batoclimab 340 mg
Trial: 35412356
Drug: Camostat mesylate
RxNorm normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesylate 200 mg dosed four times daily
Trial: 35412356
Drug: Camostat mesylate
RxNorm normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesylate at 3-fold higher dosing
Trial: 35413092
Drug: Romiplostim (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (1 μg/kg titrated to 10 μg/kg, administered weekly)
Trial: 35413279
Drug: Defibrotide (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (6.25 mg/kg/dose IV q6h) for 7 days
Trial: 35413794
Drug: hs-cTnT ≥14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT ≥14 ng/L
Trial: 35413794
Drug: hs-cTnT <14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT <14 ng/L
Trial: 35413794
Drug: NT-proBNP ≥300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP ≥300 pg/ml
Trial: 35413794
Drug: NT-proBNP <300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP <300 pg/ml
Trial: 35413794
Drug: Both hs-cTnT
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both hs-cTnT ≥14 ng/L and NT-proBNP ≥300 pg/ml
Trial: 35414025
Drug: Small-molecule compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-molecule compounds targeting regulated cell death (RCD) subroutines, including narciclasine, torin-1 combined with chloroquine, ONC201, and NCT03733119.
Trial: 35414591
Drug: Enoblituzumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoblituzumab (15 mg/kg) plus pembrolizumab (2 mg/kg) every 3 weeks
Trial: 35416053
Drug: Avelumab maintenance
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab maintenance treatment plus best supportive care
Trial: 35416669
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor and palbociclib
Trial: 35416710
Drug: Nifurtimox (NF)
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox (NF) treatment
Trial: 35417089
Drug: Echocardiographic red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echocardiographic red flags for AC (apical sparing or a combination of ≥2 other red flags)
Trial: 35417530
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of HDAC inhibitors (panobinostat or romidepsin) and ClpP activators (ONC206 and ONC212)
Trial: 35417530
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of HDAC inhibitors and imipridones
Trial: 35417637
Drug: Rilzabrutinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib (200 mg once daily, 400 mg once daily, 300 mg twice daily, 400 mg twice daily)
Trial: 35417637
Drug: Rilzabrutinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib (400 mg twice daily)
Trial: 35417637
Drug: Rilzabrutinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib (all dose levels)
Trial: 35417638
Drug: Mitapivat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitapivat (5 mg twice daily, with potential escalation to 20 or 50 mg twice daily)
Trial: 35418154
Drug: Watch antibiotics
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watch antibiotics (e.g., ceftriaxone, ciprofloxacin)
Trial: 35418154
Drug: Watch antibiotics
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watch antibiotics
Trial: 35418154
Drug: Access antibiotics
RxNorm normalized name: ACCESS PIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access antibiotics
Trial: 35418159
Drug: C1M in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1M in mice treated with CP17 (neutrophil infiltration inhibitor)
Trial: 35418329
Drug: Vaginal pH
RxNorm normalized name: Azo Vaginal pH Test Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal pH modulator (VPM; Phexxi)
Trial: 35418436
Drug: COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine awareness and acceptance
Trial: 35418436
Drug: Perceived effectiveness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived effectiveness and safety of COVID-19 vaccines
Trial: 35418586
Drug: Nonstandard wearing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonstandard wearing of face masks, longer time of face mask wearing, reduced outdoor time, decreased daily reading time, shortened visual display terminals time, dry environment
Trial: 35419649
Drug: Usual pNET
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual pNET treatments (chemotherapies and somatostatin analogues)
Trial: 35420493
Drug: Tebipenem pivoxil
RxNorm normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebipenem pivoxil hydrobromide (TBP-PI-HBr); specific dosage and duration not mentioned.
Trial: 35420628
Drug: Cabozantinib, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib, 60 mg orally once daily until disease progression, unacceptable toxic effects, or withdrawal of consent.
Trial: 35421287
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine system, details on dosage and duration not available
Trial: 35422607
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (IVT-AFL) with sham laser
Trial: 35422607
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (IVT-AFL) with micropulse (MP) laser
Trial: 35425788
Drug: DHA (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (800 mg/day) and EPA (25 mg/day) supplementation for 6 months
Trial: 35425930
Drug: Ketogenic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Trial: 35425930
Drug: Standard high-carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard high-carbohydrate diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Trial: 35425985
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg once daily added to stable combined ART for 5 days
Trial: 35426046
Drug: Other options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other options (other G-CSF or none)
Trial: 35427833
Drug: Poststudy salvage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Poststudy salvage treatment
Trial: 35428211
Drug: IV injection
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection of low activity benzamide-based radioligands targeting melanin
Trial: 35428346
Drug: Dual-tDCS during
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-tDCS during physical therapy (2 mA for 20 minutes)
Trial: 35428657
Drug: Autologous, ex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous, ex vivo expanded Tregs infusion (1×10^6 cells)
Trial: 35429115
Drug: Circulating proteins
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating proteins related to adipokine signaling and vascular function (e.g., leptin, vascular endothelial growth factor) in women
Trial: 35429115
Drug: Circulating proteins
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating proteins related to extracellular matrix organization and inflammation (e.g., matrix metalloproteinase-2, C-reactive protein) in men
Trial: 35429329
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg daily), Dexamethasone (20-40 mg weekly), Daratumumab (16 mg/kg)
Trial: 35429391
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2) and Carboplatin (target AUC 6) intravenously every 3 weeks for up to 6 cycles
Trial: 35429391
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and Carboplatin chemotherapy
Trial: 35430299
Drug: Combination immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination immunotherapy for HCC
Trial: 35431912
Drug: Psilocybin Assisted
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin Assisted Therapy
Trial: 35432163
Drug: Prism Adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism Adaptation Treatment (PAT)
Trial: 35432163
Drug: Alternative therapies
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapies (Control)
Trial: 35432352
Drug: Anti-CD30 CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD30 CAR-T therapy combined with PD-1 inhibitor
Trial: 35432352
Drug: Lymphocyte-depleting chemotherapy
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphocyte-depleting chemotherapy with fludarabine and cyclophosphamide
Trial: 35433774
Drug: Probiotic intake
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic intake (from yoghurts or dietary supplements)
Trial: 35434343
Drug: Pembrolizumab given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab given 2-3 weeks prior to chemoradiation and then, q21 days concurrently with high-dose cisplatin and radiation prescribed to a total dose of 70 Gy.
Trial: 35434725
Drug: Allopurinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100 mg daily, titrated to 800 mg)
Trial: 35434725
Drug: Febuxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40 mg daily, titrated to 120 mg)
Trial: 35434725
Drug: Allopurinol and
RxNorm normalized name: Allopurinol and lesinurad only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol and Febuxostat (both treatments)
Trial: 35435222
Drug: Virus-specific antibodies
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus-specific antibodies (IgM/IgG) and T-cell responses (CD4+/CD8+)
Trial: 35435222
Drug: Virus-specific antibodies
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus-specific antibodies (IgM/IgG) only
Trial: 35435222
Drug: Virus-specific antibodies
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus-specific antibodies
Trial: 35435625
Drug: Tarloxotinib 150
RxNorm normalized name: Tarloxotinib
DrugBank: Tarloxotinib (DB14944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarloxotinib 150 mg/m2 on days 1, 8, 15, and 22 in a 28-day cycle
Trial: 35435984
Drug: Autologous CD7-CAR
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CD7-CAR T-cell infusion
Trial: 35436365
Drug: Transdermal 17β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β oestradiol (17βE) starting dose of 12.5 mcg increasing to 25 mcg after 4 months, patch changed twice weekly for a total of 8 months
Trial: 35436365
Drug: Transdermal 17β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β oestradiol (17βE)
Trial: 35437075
Drug: POMAQ and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POMAQ and ancillary sources (e.g. electronic medical records, urine toxicity screen)
Trial: 35438082
Drug: Aerobic interval
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic interval training intervention (3-weekly, 4-month duration)
Trial: 35438144
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals treatment for hepatitis C
Trial: 35438338
Drug: Web-based oncofertility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based oncofertility support tool (Preparation for Decision-Making Scale for patients)
Trial: 35438338
Drug: Web-based oncofertility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based oncofertility support tool (Preparation for Decision-Making Scale for healthcare providers)
Trial: 35439028
Drug: Narsoplimab (OMS721),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narsoplimab (OMS721), intravenous once weekly for 4-8 weeks
Trial: 35439166
Drug: T cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell receptor (TCR) immunosequencing assay
Trial: 35439298
Drug: Recombinant von
RxNorm normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant von Willebrand factor (rVWF; vonicog alfa) prophylaxis, starting dose 50 ± 10 VWF:RCo IU/kg twice weekly for 12 months (prior on-demand group)
Trial: 35439298
Drug: Recombinant von
RxNorm normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant von Willebrand factor (rVWF; vonicog alfa) prophylaxis based on prior plasma-derived VWF (pdVWF) weekly dose/dosing frequency for 12 months (switch group)
Trial: 35439353
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg administered orally
Trial: 35440569
Drug: Pharmacologic interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacologic interventions targeting AKT mutations, specific details on dosage and duration not available
Trial: 35441164
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine (two doses, 0-14 days apart)
Trial: 35441935
Drug: Nonsteroidal mineralocorticoid
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal mineralocorticoid receptor antagonists (NS-MRAs), specifically finerenone
Trial: 35442137
Drug: single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single agent PF-04518600 (OX40 agonist monoclonal antibody)
Trial: 35442137
Drug: azacitidine +
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azacitidine + avelumab (anti-PD-L1 monoclonal antibody) + GO
Trial: 35442228
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline measurement before treatment)
Trial: 35442228
Drug: Acid-blocking medications
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-blocking medications
Trial: 35442238
Drug: Sebelipase alfa
RxNorm normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa 1.0 mg/kg by intravenous infusion every other week for up to 144 weeks (with dose escalation to 3.0 mg/kg qow and subsequently to 3.0 mg/kg weekly permitted)
Trial: 35442962
Drug: Omeprazole and
RxNorm normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole and amoxicillin/clarithromycin
Trial: 35442962
Drug: Omeprazole and
RxNorm normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole and amoxicillin/levofloxacin
Trial: 35443252
Drug: PIM1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PIM1 inhibitor SGI-1776
Trial: 35443252
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of SGI-1776
Trial: 35443783
Drug: Facilitated subcutaneous
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated subcutaneous immunoglobulin treatment
Trial: 35443947
Drug: Blonanserin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blonanserin (4 mg P.O. twice per day, increased to 8-16 mg/d for 26 weeks, max 24 mg/day)
Trial: 35443984
Drug: Initial antihypertensive
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antihypertensive class
Trial: 35444059
Drug: BEMPEG (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEMPEG (0.8 mg/kg; intravenously) + NKTR-262 (0.5 mg/kg; intratumoral)
Trial: 35444471
Drug: Increased intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased intake of fish and fresh fruits, drinking water, and use of oral contraceptive pills
Trial: 35444567
Drug: Expectation-optimised video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectation-optimised video with patients giving additional information about their mostly positive therapy outcomes
Trial: 35445027
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Non-HLA-Matched Off-the-Shelf
Trial: 35446934
Drug: CD19-CAR T-cell
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-CAR T-cell therapy
Trial: 35446944
Drug: Favipiravir (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir (1800 mg BID day 1, 800 mg BID days 2-10)
Trial: 35447145
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% imiquimod cream, applied 3 times a week for 16 weeks
Trial: 35448002
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg daily during HSRT, adjuvant d1-14 every 3 weeks)
Trial: 35449189
Drug: Iontophorised Acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophorised Acetylcholine (ACh) at 5 concentrations (0.0001% to 1%) administered via three consecutive pulses of 0.02 mA for 10 min each
Trial: 35449247
Drug: Carbohydrate ingestion
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate ingestion group (400 mL of carbohydrate-containing fluid two hours prior to surgery)
Trial: 35449533
Drug: Guideline directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline directed oral anticoagulants (OACs) including direct oral anticoagulants (DOACs)
Trial: 35450679
Drug: Unplanned DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unplanned DAPT discontinuation